Share This Page
Patent: 6,235,004
✉ Email this page to a colleague
Summary for Patent: 6,235,004
| Title: | Injection syringe | ||||||||||||||||||||||||||||||
| Abstract: | The present invention provides an injection syringe comprises a housing including a holder for containing a cartridge of medicine, a piston rod with a non-circular cross-section having an outer thread, a piston rod drive, a one way coupling having an annular ring of internal ratchet notches, which annular ring can be integral with the housing, and a pawl having at least a pair of resilient arms each having a free end. | ||||||||||||||||||||||||||||||
| Inventor(s): | Steenfeldt-Jensen; S.o slashed.ren (Hornb.ae butted.k, DK), Hansen; Steffen (Hiller.o slashed.d, DK) | ||||||||||||||||||||||||||||||
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) | ||||||||||||||||||||||||||||||
| Application Number: | 09/429,677 | ||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,235,004 | ||||||||||||||||||||||||||||||
| Patent Claims: | see list of patent claims | ||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims summary: | United States Patent 6,235,004 (Medication Delivery Pen): Claim Validity, Scope, and LandscapeWhat does U.S. Patent 6,235,004 claim, in concrete mechanical terms?U.S. Patent 6,235,004 claims a medication delivery pen (cartridge-based) that converts a user input rotation into axial distal movement of a threaded, non-circular piston rod, while preventing proximal-back movement through a ratcheting one-way coupling coupled to the piston-rod drive. The independent claim is claim 1, with additional dependents (claims 2 to 5) and alternative independent formulations (claims 6 to 11). Claim 1 core combination (mechanical structure and coupling)Claim 1 ties together three elements that must co-exist:
Claim 2 to 5: tightening of geometryThese dependents narrow how the resilient arms and the notch edges are arranged:
Claim 6 to 10: alternative phrasing with similar substanceClaims 6 to 10 repeat the core architecture but with modified emphasis:
Claim 11: broader “member coupling” formulationClaim 11 rewrites the piston-rod drive and one-way coupling at a higher level of abstraction:
Claim 11 is structurally less tied to “steep front edge” plus “ramp-shaped trailing edge” language, depending on how a court construes “ratchet notches” and the directional logic of the resilient arms. How broad or narrow is the claim scope?The claim scope depends on whether infringement requires the precise notch-edge geometry and the specific coupling logic. Narrowing features present in claims 1 and 6Claims 1 and 6 explicitly require:
This is a specific ratchet profile and a specific anti-reverse mechanism: the “steep front edge” and “ramp trailing edge” shape is not optional in these independent claims. Potential scope expansion through claim 11Claim 11 does not use the “steep front edge” and “ramp-shaped trailing edge” terms verbatim in the excerpted claim text. It defines:
That gives claim 11 more room to cover designs where anti-reverse is achieved with ratchet tooth geometry that is functionally equivalent to a steep/abutting edge, even if not described exactly the same way. The trade-off is that claim 11 still requires equally spaced internal ratchet notches and resilient arms. What validity pressure points arise from the claim structure?Without the prosecution history and without direct citation of prior art documents in the prompt, the critique centers on claim-internal patentability and typical anticipation/obviousness vectors in electromechanical and mechanical pen drivers. 1) Combination claim risk: drive + anti-reverse ratchetClaims 1 and 6 are combination claims. A common invalidity pathway is showing a prior art medication delivery pen that already had:
If either component existed in a single reference, anticipation is possible. If separately, obviousness becomes the issue. 2) Ratchet tooth profile limitationClaims 1 and 6 require “steep front edge” and “ramp-shaped trailing edge.” That is a measurable geometry limitation, but it may also map onto common ratchet tooth profiles (square/abutting front with sloped return face). If prior art uses conventional ratchet teeth, an examiner or challenger can argue the prior art teeth meet those descriptors. 3) “Self-locking thread connection” breadth“Self-locking thread” usually describes a thread friction condition preventing back-driving under certain load/angle assumptions. Mechanical pens often rely on thread friction and/or geometry. This phrase can be construed broadly as a functional property. That can be attacked under indefiniteness only in extreme cases, but more often it becomes an enablement/obviousness argument: prior art thread drives are often self-retaining depending on pitch and material pairings. 4) Anti-rotation features and cross-section non-circularityThe piston rod is explicitly not circular and is mated with a rotatable drive part so that rotation translates to axial motion without uncontrolled rod rotation. Many pen mechanisms use keyed rods, splines, or flats. That is a standard design pattern that can increase obviousness risk if the remaining ratchet features are also standard. 5) Resilient arms pawl designThe pawl “surrounding said piston rod” with at least two resilient arms and arm free-end engagement is a fairly specific mechanical architecture. Still, resilient multi-arm pawls are common in one-way mechanisms. The distinctiveness will hinge on how the pawl interfaces with the internal ratchet notches and how the abutment prevents proximal rotation. Patent landscape implicationsU.S. Patent 6,235,004’s landscape posture depends on whether the asserted claim elements align with common commercial architecture for cartridge-based injection pens. Likely competitive design-around axesA competitor seeking to avoid the literal scope can target:
Litigation leverage
Claim chart style breakdown (what must be proven)Below is a strict element-by-element checklist for independent claim 1. It reflects what an infringer would have to have for each limitation.
Key risks for enforcement
Key Takeaways
FAQs1) Which independent claim is most likely to be asserted in a tight infringement case?Claims 1 and 6, because they explicitly require the notch profile with a steep front edge and ramp-shaped trailing edge and the abutting anti-reverse logic. 2) Which independent claim offers the broadest coverage?Claim 11 is broader in how it describes the anti-reverse coupling as member interaction with first vs second rotational direction prevention, while remaining consistent with internal ratchet notches and resilient arms. 3) What single design feature most often enables a design-around?The ratchet tooth profile and the abutment geometry tied to “steep front edge” versus “ramp-shaped trailing edge,” because those terms can be evaluated as mechanical structure. 4) Does the patent require the piston rod to be non-rotating in operation?The claims require a not circular cross-section and mating with a drive part, which functionally controls rotation. They do not expressly require “no rotation,” but the mechanical pairing is integral to the translation-to-axial-drive architecture. 5) How does the anti-reverse coupling relate to proximal piston movement?The anti-reverse coupling blocks pawl rotation in the direction that would transport the piston rod proximally, achieved by arm free ends engaging internal ratchet notches and abutting the steep front edge. References[1] United States Patent 6,235,004, “Medication delivery pen,” claim text as provided in the prompt. More… ↓ |
Details for Patent 6,235,004
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | June 07, 2000 | ⤷ Start Trial | 2019-10-28 |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | January 19, 2001 | ⤷ Start Trial | 2019-10-28 |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | April 23, 2004 | ⤷ Start Trial | 2019-10-28 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,235,004
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 99714 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 9938554 | ⤷ Start Trial |
| United States of America | RE43834 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
